Strategic Focus Targeted immunotherapy platform with Nexvax2 for celiac disease and expansion to other HLA-associated autoimmune diseases presents opportunity to partner on diagnostics, companion diagnostics, and expanded vaccine programs.

Clinical Momentum Advancing Nexvax2 toward phase 2 and ongoing vaccine programs signals near-term engagement potential with CROs, clinical services, and manufacturing partners to support trials and scale.

Early Stage Scale Small company size and sub-$1M revenue indicate a need for strategic collaborations, licensing, or co-development deals with larger biotech or pharma to accelerate development and commercialization.

Diagnostics Synergy Development of diagnostic and monitoring tools for celiac disease creates cross-sell potential with lab services, clinical diagnostics partners, and digital health analytics platforms.

Innovation Partnerships Backed by venture investor network and focus on autoimmune vaccines offers avenues for strategic investments, research collaborations, and technology licensing to extend the immunology platform.